Plomestane

Plomestane
Systematic (IUPAC) name
10H-(2-propynyl)-estr-4-ene-3,17-dione
Clinical data
Identifiers
77016-85-4
None
PubChem CID 9904788
ChemSpider 8080442
Chemical data
Formula C21H26O2
310.430 g/mol

Plomestane (INN, USAN; MDL-18,962), also referred to as propargylestrenedione (PED), is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer.[1][2][3][4][5] It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration.[5] However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.[6]

References

  1. ↑ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1635. ISBN 978-0-412-46630-4. Retrieved 19 May 2012.
  2. ↑ Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 227. ISBN 978-0-7514-0499-9. Retrieved 20 May 2012.
  3. ↑ Bentham Science Publishers (June 1995). Current Pharmaceutical Design. Bentham Science Publishers. p. 45. Retrieved 20 May 2012.
  4. ↑ Richard B. Kreider; Brian C. Leutholtz; Frank I. Katch; Victor L. Katch (2009). Exercise and Sport Nutrition. Exercise & Sport Nutrition. p. 350. ISBN 978-0-9742965-6-2. Retrieved 20 May 2012.
  5. ↑ 5.0 5.1 Kelloff GJ, Lubet RA, Lieberman R et al. (January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 7 (1): 65–78. PMID 9456245.
  6. ↑ Carmen Avendaño; J. Carlos Menéndez (4 June 2008). Medicinal Chemistry of Anticancer Drugs. Elsevier. p. 69. ISBN 978-0-444-52824-7. Retrieved 20 May 2012.